Reata receives FDA approval for SKYCLARYS to treat Friedreich’s Ataxia
SKYCLARYS is an oral, once-daily medication, indicated for the treatment of Friedreich’s ataxia, an ultra-rare, inherited neurodegenerative disorder,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Mar 23
SKYCLARYS is an oral, once-daily medication, indicated for the treatment of Friedreich’s ataxia, an ultra-rare, inherited neurodegenerative disorder,…
01 Mar 23
The approval was based on findings from the SAPHYR phase 3 clinical trial in which 28% of patients…
28 Feb 23
Mayne’s portfolio to be acquired comprises around 45 commercial products, four pipeline products and 40 regulatory-approved non-marketed products,…
28 Feb 23
Seagen has developed drugs like Adcetris, Tivdak, and Padcev based on its proprietary ADC technology
27 Feb 23
China’s NMPA approval is based on results from the DESTINY-Breast03 clinical trial, in which Enhertu showed a 72%…
27 Feb 23
The positive opinion was adopted on the basis of a phase 3 trial that showed superior survival outcomes…
24 Feb 23
Capsida will receive $70m, which includes upfront payments and potential equity investment, and is eligible to receive up…
24 Feb 23
Previously referred to as efanesoctocog alfa, ALTUVIIIO is approved for routine prophylaxis and on-demand treatment to control bleeding…
23 Feb 23
The collaboration combines Moderna's mRNA platform with Life Edit's gene editing technologies, including base editing capabilities, to advance…
23 Feb 23
The White Label World Expo UK will feature a range of inspiring seminars, interactive masterclasses and innovations, covering…